PCM
TEVA icon

Palisade Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Palisade Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-18,100
Closed -$319K – 452
2017
Q3 		$319K Buy
18,100
+2,578
+17% +$58K 0.01% 385
2017
Q2 		$516K Sell
15,522
-2,000
-11% -$61.9K 0.02% 377
2017
Q1 		$562K Sell
17,522
-4,100
-19% -$140K 0.02% 362
2016
Q4 		$784K Buy
21,622
+5,600
+35% +$224K 0.03% 355
2016
Q3 		$737K Buy
16,022
+3,500
+28% +$183K 0.03% 452
2016
Q2 		$629K Buy
+12,522
New +$667K 0.02% 448
2014
Q3 		– Sell
-65,722
Closed -$3.44M – 495
2014
Q2 		$3.44M Sell
65,722
-9,300
-12% -$475K 0.08% 300
2014
Q1 		$3.96M Sell
75,022
-8,500
-10% -$393K 0.1% 278
2013
Q4 		$3.35M Buy
+83,522
New +$3.29M 0.09% 284

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

Palisade Capital Management's TEVA Position: Q4 2017 in Review

Palisade Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2017, closing a stake of 18,100 shares — an estimated $319K sold.

Palisade Capital Management first reported a position in TEVA in Q4 2013 and held it in 9 quarters. The position peaked at $3.96M in Q1 2014. 507 funds tracked by Wall St. Rank hold TEVA as of Q4 2017.

  • Palisade Capital Management reported no remaining Teva Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Palisade Capital Management sold 18,100 Teva Pharmaceuticals shares in Q4 2017, an estimated $319K.
  • Palisade Capital Management first reported a position in Teva Pharmaceuticals in Q4 2013 and held it in 9 quarters.
  • Palisade Capital Management's Teva Pharmaceuticals position peaked at $3.96M in Q1 2014.
  • 507 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2017.

Based on Palisade Capital Management's 13F filing for Q4 2017, filed 9 Feb 2018.